DISCOUNT-ZERTIFIKAT - DERMAPHARM HOLDING Share Price

Certificat

DE000DJ08N94

Delayed Deutsche Boerse AG 11:34:47 29/05/2024 BST
35.25 EUR -2.14% Intraday chart for DISCOUNT-ZERTIFIKAT - DERMAPHARM HOLDING
Current month+19.31%
1 month+17.41%
Date Price Change
29/05/24 35.25 -2.14%
28/05/24 36.02 -0.19%
27/05/24 36.09 +0.31%
24/05/24 35.98 -1.40%
23/05/24 36.49 -0.25%

Delayed Quote Deutsche Boerse AG

Last update May 29, 2024 at 11:34 am

More quotes

Static data

Product typeDiscount Certificates
Buy / SellCALL
Underlying DERMAPHARM HOLDING SE
Issuer DZ BANK
WKN DJ08N9
ISINDE000DJ08N94
Date issued 21/04/2023
Maturity 20/12/2024 (206 Days)
Parity 1 : 1
Emission price 39.35
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 42.22
Lowest since issue 30.19
Spread 0.1
Spread %0.28%

Company Profile

Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Sector
-
More about the company

Ratings for Dermapharm Holding SE

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Dermapharm Holding SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
36.9 EUR
Average target price
56.9 EUR
Spread / Average Target
+54.20%
Consensus